We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medicines Company to Sell Infectious Disease Unit to Melinta
Read MoreHide Full Article
The Medicines Company announced that it has entered into a definitive agreement with antibiotics company, Melinta Therapeutics, Inc. , for selling its infectious disease business unit for an upfront payment of $270 million. The agreement will grant Melinta worldwide rights of Orbactiv, Minocin and recently launched Vabomere.
The Medicines Company plans to focus on developing its pivotal pipeline candidate — inclisiran — for treating hypercholesterolemia.
The Medicines Company’s shares have fallen 11.1% so far this year, underperforming the industry’s rise of 1.3% in that period.
Per the cash and stock deal, Melinta will pay $215 million in cash, including $165 million at the time of the closing of the deal, and $55 million in common stock.
The Medicine Company will receive royalties in the range of 5%-25% on Vabomere U.S. sales, 5%-15% on U.S. sales of Minocin & Orbactiv, and 15% on international sales of all the drugs.
The Medicine Company plans to focus on the development of inclisiran, which is currently being evaluated in a phase III study for the treatment of hypercholesterolemia. The company has burnt significant cash this year. This deal will help the company to recoup a major portion of it. Moreover, the cash will help to continue the inclisiran study till its anticipated completion in 2019.
The deal is expected to close in the first quarter of 2018.
Meanwhile, the company, as part of its earlier announced restructuring program, will cut its headcount by 60. This will also reduce its annual operating expenses.
Ligand’s earnings estimates were increased from $2.96 to $2.97 for 2017 and increased from $3.68 to $3.70 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 8.22%. The company’s shares have returned 28.8% so far this year.
ACADIA’s loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Medicines Company to Sell Infectious Disease Unit to Melinta
The Medicines Company announced that it has entered into a definitive agreement with antibiotics company, Melinta Therapeutics, Inc. , for selling its infectious disease business unit for an upfront payment of $270 million. The agreement will grant Melinta worldwide rights of Orbactiv, Minocin and recently launched Vabomere.
The Medicines Company plans to focus on developing its pivotal pipeline candidate — inclisiran — for treating hypercholesterolemia.
The Medicines Company’s shares have fallen 11.1% so far this year, underperforming the industry’s rise of 1.3% in that period.
Per the cash and stock deal, Melinta will pay $215 million in cash, including $165 million at the time of the closing of the deal, and $55 million in common stock.
The Medicine Company will receive royalties in the range of 5%-25% on Vabomere U.S. sales, 5%-15% on U.S. sales of Minocin & Orbactiv, and 15% on international sales of all the drugs.
The Medicine Company plans to focus on the development of inclisiran, which is currently being evaluated in a phase III study for the treatment of hypercholesterolemia. The company has burnt significant cash this year. This deal will help the company to recoup a major portion of it. Moreover, the cash will help to continue the inclisiran study till its anticipated completion in 2019.
The deal is expected to close in the first quarter of 2018.
Meanwhile, the company, as part of its earlier announced restructuring program, will cut its headcount by 60. This will also reduce its annual operating expenses.
The Medicines Company Price
The Medicines Company Price | The Medicines Company Quote
Zacks Rank & Stocks to Consider
The Medicines Company carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. (LGND - Free Report) and ACADIA Pharmaceuticals Inc. (ACAD - Free Report) . Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ligand’s earnings estimates were increased from $2.96 to $2.97 for 2017 and increased from $3.68 to $3.70 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 8.22%. The company’s shares have returned 28.8% so far this year.
ACADIA’s loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>